Abstract:The development of safe and effective broad-spectrum antivirals that target the replication machinery of respiratory viruses is of high priority in pandemic preparedness programs. Here, we studied the mechanism of action of a newly discovered nucleotide analog against diverse RNA-dependent RNA polymerases (RdRp) of prototypic respiratory viruses. GS-646939 is the active 5′-triphosphate (TP) metabolite of a 4ʹ-cyano modified -adenosine analog phosphoramidate prodrug GS-7682. Enzyme kinetics show that the RdRps of human rhinovirus type 16 (HRV-16) and enterovirus 71 (EV-71) incorporate GS-646939 with unprecedented selectivity; GS-646939 is incorporated 20-50-fold more efficiently than its natural ATP counterpart. The RdRp complex of respiratory syncytial virus (RSV) and human metapneumovirus (HMPV) incorporate GS-646939 and ATP with similar efficiency. In contrast, influenza B RdRp shows a clear preference for ATP and human mitochondrial RNA polymerase (h-mtRNAP) does not show significant incorporation of GS-646939. Once incorporated into the nascent RNA strand, GS-646939 acts as a chain-terminator although higher NTP concentrations can partially overcome inhibition for some polymerases. Modeling and biochemical data suggest that the 4ʹ-modification inhibits RdRp translocation. Comparative studies with GS-443902, the active triphosphate form of the 1′-cyano modified prodrugs remdesivir and obeldesivir, reveal not only different mechanisms of inhibition, but also differences in the spectrum of inhibition of viral polymerases. In conclusion, 1ʹ-cyano and 4ʹ-cyano modifications of nucleotide analogs provide complementary strategies to target the polymerase of several families of respiratory RNA viruses.

What problem does this paper attempt to address?

The main problem that this paper attempts to solve is to develop a broad - spectrum antiviral drug, especially targeting the replication mechanism of respiratory RNA viruses. Specifically, the research focuses on exploring the inhibition mechanism and profile of a newly discovered nucleotide analogue GS - 646939 on the RNA - dependent RNA polymerase (RdRp) of multiple respiratory RNA viruses. GS - 646939 is the active 5' - triphosphate metabolite of the 4' - cyano - modified C - adenosine analogue, and its prodrug form is GS - 7682. ### Main problems: 1. **Broad - spectrum antiviral activity**: The research aims to evaluate the inhibitory effect of GS - 646939 on the RdRp of multiple respiratory RNA viruses to determine whether it has broad - spectrum antiviral activity. 2. **Mechanism of action**: Explore how GS - 646939 is recognized and bound by the RdRp of different viruses, and its specific inhibitory mechanism in the RNA synthesis process. 3. **Comparison with existing drugs**: Compare the mechanism of action and inhibitory profile of GS - 646939 with the known 1' - cyano - modified C - adenosine analogue GS - 443902 to reveal the differences and complementarities between the two. ### Specific objectives: - **Selective binding**: Evaluate the selective binding efficiency of GS - 646939 in different virus RdRps, especially compared with natural ATP. - **Chain termination mechanism**: Study the chain termination mechanism of GS - 646939 in the RNA synthesis process, including immediate chain termination and delayed chain termination. - **Structural basis**: Analyze the binding mode of GS - 646939 at the RdRp active site through structural modeling to explain the molecular basis of its selectivity and inhibitory mechanism. - **Template - dependent inhibition**: Evaluate the effect of GS - 646939 on subsequent nucleotide incorporation after being embedded in the template, and compare it with the template - dependent inhibition mechanism of GS - 443902. ### Research background: - **Respiratory RNA viruses**: These viruses include coronaviruses (such as SARS - CoV - 2), picornaviruses (such as HRV - 16 and EV - 71), pneumoviruses (such as RSV and HMPV), paramyxoviruses (such as HPIV - 3 and PIV - 5) and influenza viruses (such as influenza B virus). - **Importance of RdRp**: RdRp is a key enzyme for the replication of these viruses and is therefore an important target for the development of broad - spectrum antiviral drugs. - **Existing drugs**: For example, Remdesivir and its active metabolite GS - 443902 have shown effective inhibitory effects on some viruses, but their mechanisms of action and profiles still need further study. Through these studies, the paper aims to provide a scientific basis for the development of more effective broad - spectrum antiviral drugs and new strategies for dealing with emerging viruses that may appear in the future.

Mechanism and spectrum of inhibition of a 4’-cyano modified nucleotide analog against diverse RNA polymerases of prototypic respiratory RNA viruses

Inhibition of SARS-CoV-2 polymerase by nucleotide analogs from a single-molecule perspective

2′- and 3′-Ribose Modifications of Nucleotide Analogues Establish the Structural Basis to Inhibit the Viral Replication of SARS-CoV-2

Binding Mechanism of the Active Form of Molnupiravir to RdRp of SARS-CoV-2 and Designing Potential Analogues: Insights from Molecular Dynamics Simulations

Efficient incorporation and template-dependent polymerase inhibition are major determinants for the broad-spectrum antiviral activity of remdesivir

The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus

Mechanism of Inhibition of Ebola Virus RNA-Dependent RNA Polymerase by Remdesivir

Discovery of GS-7682, a Novel 4'-Cyano-Modified C -Nucleoside Prodrug with Broad Activity against Pneumo- and Picornaviruses and Efficacy in RSV-Infected African Green Monkeys

Nucleotide analogues as inhibitors of SARS-CoV Polymerase

Discovery and Synthesis of GS-7682, a Novel Prodrug of a 4′-CN-4-Aza-7,9-Dideazaadenosine -Nucleoside with Broad-Spectrum Potency Against Pneumo- and Picornaviruses and Efficacy in RSV-Infected African Green Monkeys

Oral GS-441524 derivatives: Next-generation inhibitors of SARS‐CoV‐2 RNA‐dependent RNA polymerase

Development of an allosteric inhibitor class blocking RNA elongation by the respiratory syncytial virus polymerase complex

Development of a Simple in Vitro Assay to Identify and Evaluate Nucleotide Analogs Against SARS-CoV-2 RNA-Dependent RNA Polymerase

Structure-Activity Relationship of Oxacyclo- and Triazolo-Containing Respiratory Syncytial Virus Polymerase Inhibitors

Identifying Small-Molecule Inhibitors of SARS-CoV-2 RNA-Dependent RNA Polymerase by Establishing a Fluorometric Assay

A pan-respiratory antiviral chemotype targeting a transient host multi-protein complex

Nucleosides for the treatment of respiratory RNA virus infections

Novel analogues of a nonnucleoside SARS-CoV-2 RdRp inhibitor as potential antivirotics

Allosteric Activation of SARS-CoV-2 RNA-Dependent RNA Polymerase by Remdesivir Triphosphate and Other Phosphorylated Nucleotides

Chain Termination Effects of Chemically Modified Nucleoside Analogs on SARS-CoV-2 RNA Polymerase

Favipiravir Analogues as Inhibitors of SARS-CoV-2 RNA-Dependent RNA Polymerase, Combined Quantum Chemical Modeling, Quantitative Structure–Property Relationship, and Molecular Docking Study